Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Current Deferred Revenue (2021 - 2025)

ARS Pharmaceuticals' Current Deferred Revenue history spans 5 years, with the latest figure at $609000.0 for Q4 2025.

  • For Q4 2025, Current Deferred Revenue rose 9.34% year-over-year to $609000.0; the TTM value through Dec 2025 reached $609000.0, up 9.34%, while the annual FY2025 figure was $609000.0, 9.34% up from the prior year.
  • Current Deferred Revenue for Q4 2025 was $609000.0 at ARS Pharmaceuticals, up from $526000.0 in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $3.1 million in Q4 2022 and bottomed at $10000.0 in Q1 2023.
  • The 5-year median for Current Deferred Revenue is $609000.0 (2025), against an average of $1.2 million.
  • The largest annual shift saw Current Deferred Revenue surged 115.31% in 2022 before it tumbled 82.03% in 2024.
  • A 5-year view of Current Deferred Revenue shows it stood at $1.5 million in 2021, then surged by 115.31% to $3.1 million in 2022, then dropped by 1.18% to $3.1 million in 2023, then crashed by 82.03% to $557000.0 in 2024, then grew by 9.34% to $609000.0 in 2025.
  • Per Business Quant, the three most recent readings for SPRY's Current Deferred Revenue are $609000.0 (Q4 2025), $526000.0 (Q3 2025), and $746000.0 (Q2 2025).